BiotechTube
Geistlich Pharma

Geistlich Pharma

Wolhusen, Switzerland· Est.
geistlich.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Geistlich Pharma is a privately held, commercial-stage Swiss medtech company with a 175-year history, now focused as 'The Regeneration Expert.' It holds a dominant position in the dental biomaterials market with flagship products like Bio-Oss® and Bio-Gide® for bone and soft tissue regeneration. The company has successfully expanded into orthopedics with the Chondro-Gide® matrix for cartilage repair (AMIC procedure) and maintains smaller segments in infectiology and advanced wound care. Geistlich operates a global distribution network, generating significant revenue from its approved, clinically proven products.

DentistryOrthopedicsWound CareInfectiology

Technology Platform

Biomaterials of natural (bovine/porcine) origin processed into osteoconductive scaffolds and resorbable collagen membranes for guided tissue and bone regeneration (GTR/GBR) and autologous matrix-induced chondrogenesis (AMIC).

Opportunities

The global growth in dental implantology and demand for joint-preserving orthopedic procedures creates expanding markets for Geistlich's proven biomaterials.
Geographic expansion into high-growth emerging markets and further indication expansion for the AMIC procedure in orthopedics represent significant growth levers.

Risk Factors

Intense competition in the biomaterials space from synthetic and alternative biological products poses market share risks.
The company is also exposed to regulatory and supply chain complexities inherent in using animal-derived tissues, requiring rigorous quality control to mitigate safety and supply disruption risks.

Competitive Landscape

In dental biomaterials, Geistlich competes with companies like Zimmer Biomet (Cerabone), Botiss (maxgraft), and numerous synthetic bone graft producers. In orthopedic cartilage repair, competitors include Vericel (MACI), Smith & Nephew, and allograft providers. The advanced wound care space is crowded with players like Integra LifeSciences, Smith & Nephew, and Organogenesis.

More companies in Switzerland →